Boehringer Ingelheim
↗Ingelheim am Rhein, Germany (near Mainz and Frankfurt)
Boehringer Ingelheim is one of the world's largest pharmaceutical companies and the largest private pharmaceutical enterprise globally. Founded in 1885, it is headquartered in Ingelheim am Rhein, Germany, and operates in 78 countries with approximately 52,000-54,000 employees. The company is fully owned by the Boehringer, Liebrecht, and von Baumbach families. With a diversified portfolio spanning both human and animal health, Boehringer Ingelheim focuses on respiratory diseases, cardiovascular and metabolic disorders, immunology, oncology, central nervous system disorders, and animal health. The company generated revenue of EUR 26.8 billion (approximately $29 billion) in 2024, reaching 66 million patients worldwide and demonstrating consistent growth at constant exchange rates.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Integrated Pharma (Human + Animal Health)
SIZE & FINANCIALS
Employees:10000+
Revenue:$25B-$30B
Founded:1885
Ownership:private
Status:operating
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 3 (multiple candidates nearing approval)
Modalities:Small molecule, Monoclonal antibodies (mAb), Antibody-drug conjugates (ADC), Biologics, Targeted therapies
Trial Phases:-
FDA Approvals:8
CORPORATE STRUCTURE
Subsidiaries:Boehringer Ingelheim Animal Health, Boehringer Ingelheim USA Corp, Boehringer Ingelheim Vetmedica
Key Partnerships:LEO Pharma: License agreement for Spevigo (spesolimab) in generalized pustular psoriasis and other skin conditions (June 2025), Re-Vana Therapeutics: Strategic collaboration for long-acting ophthalmic therapies (July 2024, $1B deal), AimedBio (South Korea): ADC platform partnership (up to $991 million), Synaffix (Lonza subsidiary): ADC discovery platform partnership (up to $1.3 billion), Nerio Therapeutics: Acquisition of novel immune checkpoint inhibitors for immuno-oncology (July 2024, $1.3B), Gubra: CRO partnership for anti-obesity agents development including NPY2R agonist programs, Bayer: Joint development of HER2+ NSCLC therapies, Yale University: Collaboration on novel immunotherapy targets, Bill & Melinda Gates Foundation: Animal health partnership for African animal trypanosomiasis solution
COMPETITION
Position:Leader
Competitors:Roche, Merck, Pfizer, Bayer, Sanofi, AstraZeneca, Novartis, Eli Lilly +2 more
LEADERSHIP
Key Executives:
Shashank Deshpande - Chief Executive Officer and Head of Human Pharma Business Unit
Hubertus von Baumbach - Chairman of the Board of Managing Directors
Jean-Michel Boers - President and CEO, Boehringer Ingelheim USA Corp
Michael Betke-Hornfeck - Chief Purchasing Officer
Sven Sommerlatte - Chief Human Resources Officer
Scientific Founders:Albert Boehringer
LINKS
Website:boehringer-ingelheim.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Boehringer Ingelheim. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.